MLN2201
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research[1][2].
Product Specifications
Product Name Alternative
YFC51.1; LDP-01
UNSPSC
12352203
Target
Integrin
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
References & Citations
[1]Legos JJ, et al. Pharmacological interventions for stroke: failures and future. Expert Opin Investig Drugs. 2002 May;11 (5) :603-14. |[2]Legos JJ, et al. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr Opin Investig Drugs. 2003 Jul;4 (7) :847-58.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb700365 0.5 mg
Goat Rabbit IgG (H&L), F (ab) '2 fragment, Biotin conjugated Antibody
Sign In for Pricing
View Details 